CA3238026A1 - Multicyclic compounds - Google Patents

Multicyclic compounds Download PDF

Info

Publication number
CA3238026A1
CA3238026A1 CA3238026A CA3238026A CA3238026A1 CA 3238026 A1 CA3238026 A1 CA 3238026A1 CA 3238026 A CA3238026 A CA 3238026A CA 3238026 A CA3238026 A CA 3238026A CA 3238026 A1 CA3238026 A1 CA 3238026A1
Authority
CA
Canada
Prior art keywords
co2me
compound
acceptable salt
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3238026A
Other languages
English (en)
French (fr)
Inventor
Atlee Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlee Biotech Inc
Original Assignee
Atlee Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlee Biotech Inc filed Critical Atlee Biotech Inc
Publication of CA3238026A1 publication Critical patent/CA3238026A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3238026A 2021-11-13 2022-11-11 Multicyclic compounds Pending CA3238026A1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202163279094P 2021-11-13 2021-11-13
US63/279,094 2021-11-13
US202163282264P 2021-11-23 2021-11-23
US63/282,264 2021-11-23
US202263299749P 2022-01-14 2022-01-14
US63/299,749 2022-01-14
US202263317980P 2022-03-09 2022-03-09
US63/317,980 2022-03-09
US202263321915P 2022-03-21 2022-03-21
US63/321,915 2022-03-21
US202263336476P 2022-04-29 2022-04-29
US63/336,476 2022-04-29
US202263375050P 2022-09-08 2022-09-08
US63/375,050 2022-09-08
PCT/US2022/049719 WO2023086580A2 (en) 2021-11-13 2022-11-11 Multicyclic compounds

Publications (1)

Publication Number Publication Date
CA3238026A1 true CA3238026A1 (en) 2023-05-19

Family

ID=86336491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3238026A Pending CA3238026A1 (en) 2021-11-13 2022-11-11 Multicyclic compounds

Country Status (6)

Country Link
US (1) US20250100987A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429656A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024543479A (cg-RX-API-DMAC7.html)
CA (1) CA3238026A1 (cg-RX-API-DMAC7.html)
IL (1) IL312774A (cg-RX-API-DMAC7.html)
WO (1) WO2023086580A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024226703A2 (en) * 2023-04-27 2024-10-31 The Scripps Research Institute Asymmetric synthesis and diversification of a stabilized salvinorin a scaffold
CN118267384B (zh) * 2024-03-27 2024-12-20 徐州医科大学 κ阿片受体激动剂在制备预防和/或治疗颞叶癫痫药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138589A2 (en) * 2005-06-17 2006-12-28 University Of Iowa Research Foundation Opioid receptor ligands
US11512075B2 (en) * 2017-06-14 2022-11-29 The Scripps Research Institute Synthesis of 20-nor-salvinorin A
EP3773723A1 (en) * 2018-04-13 2021-02-17 BlumenTech S.L. Combination product for the induction and/or maintenance of general anesthesia
US10556889B1 (en) * 2018-12-19 2020-02-11 Blue Sky Pharmaceuticals, LLC Salvinorin derivatives

Also Published As

Publication number Publication date
JP2024543479A (ja) 2024-11-21
WO2023086580A2 (en) 2023-05-19
WO2023086580A3 (en) 2023-07-06
US20250100987A1 (en) 2025-03-27
EP4429656A2 (en) 2024-09-18
EP4429656A4 (en) 2026-01-28
IL312774A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
EP3442971B1 (en) Estrogen receptor modulators
CA2850987C (en) Substituted biaryl alkyl amides
RS59534B1 (sr) Ciklopropilamini kao lsd1 inhibitori
US20110014699A1 (en) Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use
CN106536498A (zh) 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
EP3816163A1 (en) Cell necrosis inhibitor, preparation method therefor and use thereof
JP6781148B2 (ja) ヒドロキシステロイド化合物、それらの中間体、それらの調製方法、組成物および使用
KR20240045222A (ko) 3,4-메틸렌다이옥시메스암페타민 및 관련 환각제, 그리고 이들의 용도
JP2021535909A (ja) 高活性stingタンパク質アゴニスト化合物
JP6847851B2 (ja) Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用
RS62515B1 (sr) Prekursor leka – derivat aminokiselina
US20250100987A1 (en) Multicyclic compounds
CN114149424A (zh) 用于治疗疾病的杂环化合物
CA3178798A1 (en) 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression
CN105658634A (zh) 作为TCR-Nck相互作用的抑制剂的被醇盐取代的色烯衍生物
ITMI951900A1 (it) Derivati idroisochinolinici sostituiti
CN108026029A (zh) 经选择的γ-羟基丁酸的酰胺及其在治疗酒精误用中的用途
EP4545534A1 (en) Heterocyclic compound as taar1 ligand agonist
EP4043436A1 (en) Magl inhibitor, preparation method therefor and use thereof
EP3506983B1 (en) Substituted urea-derivatives for the treatment of pain
CA2630655C (fr) Derives de isoquinoline et benzo[h]isoquinoline, leur preparation et leur utilisation en therapeutique en tant qu'antagonistes du recepteur de l'histamine h3
CN118598822A (zh) 一类含芳基的胺类化合物、其制备方法和用途
WO2024124050A1 (en) Multicyclic compounds
CA3176429A1 (en) Modulators of hemoglobin
WO2024124043A1 (en) Multicyclic compounds

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20240814

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241112

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241112

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107